Resibufogenin protects against atherosclerosis in ApoE-/- mice through blocking NLRP3 inflammasome assembly
RBG effectively inhibits NLRP3 inflammasome activation, reduces pro-inflammatory cytokine release, and decreases formation of foamy macrophages, thereby slowing the progression of AS. Although these findings highlight RBG as a promising therapeutic approach for cardiovascular diseases, further research is necessary to assess its safety and effectiveness in humans and to investigate possible synergistic effects with other treatments.
Authors
- Yijun Chen (ORCID: https://orcid.org/0000-0002-3209-8730)
- Xuegong Xu (ORCID: https://orcid.org/0000-0001-5572-0636)
- Li Chun (ORCID: https://orcid.org/0000-0002-7494-2354)
- Jun Wang (ORCID: https://orcid.org/0000-0002-7863-0331)
- Xiaoyang Chen
- Wei Wang (ORCID: https://orcid.org/0000-0003-2642-3338)
- Zijun Chen (ORCID: https://orcid.org/0000-0002-8887-0443)
- Zhai Chenguang
- Du Wanying
Institutions
- Guangzhou University of Chinese Medicine (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Zhengzhou City Hospital (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.jare.2025.04.029
- Citations
- 6
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.84